Nxera Pharma Co., Ltd. (OTCMKTS:SOLTF – Get Free Report) shares fell 4% during trading on Thursday . The company traded as low as $5.54 and last traded at $5.91. 400 shares changed hands during trading, a decline of 70% from the average session volume of 1,355 shares. The stock had previously closed at $6.16.
Nxera Pharma Stock Performance
The business has a 50 day moving average of $6.51 and a 200 day moving average of $7.38.
Nxera Pharma Company Profile
Nxera Pharma Co, Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications.
Read More
- Five stocks we like better than Nxera Pharma
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- How to Most Effectively Use the MarketBeat Earnings Screener
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- Market Cap Calculator: How to Calculate Market Cap
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Nxera Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nxera Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
